Benzinga | Feb 16, 2021 07:08AM EST

Wells Fargo Initiates Coverage On Beam Therapeutics with Overweight Rating, Announces Price Target of $145

Wells Fargo analyst Yanan Zhu initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Overweight rating and announces Price Target of $145.